Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

Cisplatin 21pembrolizumab 12Cetuximab 12Radiotherapy 11Carboplatin 10Nivolumab 9Radiotherapy, Intensity-Modulated 8Fluorouracil 8durvalumab 5Standard of Care 5epacadostat 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Drug Therapy 4Cyclophosphamide 4X-Rays 3Radiosurgery 3Radiation 3Practice Guidelines as Topic 3Panitumumab 3Gene Expression Profiling 3Docetaxel 3Biopsy 3fluoromisonidazole 2fludarabine 2cemiplimab 2aldesleukin 2Venlafaxine Hydrochloride 2Thyroxine 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × elgemtumab × Head & Neck × Clear all
NCT02143622 2016-04-21

Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients

Novartis

Phase 1/2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡